By 2003, KBI had fully embraced its CDMO identity, and by 2010, it was expanding its mammalian production capabilities in North Carolina. Today, KBI has six sites across North Carolina, Colorado, and Geneva, turning its early expertise in analytical problem-solving into a full-scale biomanufacturing operation. Its specialty? Tackling the toughest molecules.
